212 related articles for article (PubMed ID: 30835122)
1. Microtubule-Targeting Drugs: More than Antimitotics.
Kaul R; Risinger AL; Mooberry SL
J Nat Prod; 2019 Mar; 82(3):680-685. PubMed ID: 30835122
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in discovery and development of antimitotic agents.
Kiselyov A; Balakin KV; Tkachenko SE; Savchuk N; Ivachtchenko AV
Anticancer Agents Med Chem; 2007 Mar; 7(2):189-208. PubMed ID: 17348827
[TBL] [Abstract][Full Text] [Related]
3. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
4. Natural products as antimitotic agents.
Dall'Acqua S
Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
[TBL] [Abstract][Full Text] [Related]
5. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.
Steinmetz MO; Prota AE
Trends Cell Biol; 2018 Oct; 28(10):776-792. PubMed ID: 29871823
[TBL] [Abstract][Full Text] [Related]
6. How do microtubule-targeted drugs work? An overview.
Jordan MA; Kamath K
Curr Cancer Drug Targets; 2007 Dec; 7(8):730-42. PubMed ID: 18220533
[TBL] [Abstract][Full Text] [Related]
7. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.
Mohan R; Banerjee M; Ray A; Manna T; Wilson L; Owa T; Bhattacharyya B; Panda D
Biochemistry; 2006 May; 45(17):5440-9. PubMed ID: 16634625
[TBL] [Abstract][Full Text] [Related]
8. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.
Kuznetsov G; TenDyke K; Towle MJ; Cheng H; Liu J; Marsh JP; Schiller SE; Spyvee MR; Yang H; Seletsky BM; Shaffer CJ; Marceau V; Yao Y; Suh EM; Campagna S; Fang FG; Kowalczyk JJ; Littlefield BA
Mol Cancer Ther; 2009 Oct; 8(10):2852-60. PubMed ID: 19825803
[TBL] [Abstract][Full Text] [Related]
9. Natural antitubulin agents: importance of 3,4,5-trimethoxyphenyl fragment.
Negi AS; Gautam Y; Alam S; Chanda D; Luqman S; Sarkar J; Khan F; Konwar R
Bioorg Med Chem; 2015 Feb; 23(3):373-89. PubMed ID: 25564377
[TBL] [Abstract][Full Text] [Related]
10. Selective Inhibition of Spindle Microtubules by a Tubulin-Binding Quinazoline Derivative.
Sawada JI; Ishii H; Matsuno K; Sato M; Suzuki Y; Asai A
Mol Pharmacol; 2019 Nov; 96(5):609-618. PubMed ID: 31471455
[TBL] [Abstract][Full Text] [Related]
11. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
[TBL] [Abstract][Full Text] [Related]
12. Viriditoxin Stabilizes Microtubule Polymers in SK-OV-3 Cells and Exhibits Antimitotic and Antimetastatic Potential.
Su M; Zhao C; Li D; Cao J; Ju Z; Kim E; Jung YS; Jung JH
Mar Drugs; 2020 Aug; 18(9):. PubMed ID: 32867174
[TBL] [Abstract][Full Text] [Related]
13. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
Bates D; Eastman A
Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987
[TBL] [Abstract][Full Text] [Related]
14. Novel mitotic targets and their small-molecule inhibitors.
Ivachtchenko AV; Kiselyov AS; Tkachenko SE; Ivanenkov YA; Balakin KV
Curr Cancer Drug Targets; 2007 Dec; 7(8):766-84. PubMed ID: 18220536
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitosis for anti-cancer therapy.
Sudakin V; Yen TJ
BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
[TBL] [Abstract][Full Text] [Related]
16. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
17. Microtubules and actin filaments: dynamic targets for cancer chemotherapy.
Jordan MA; Wilson L
Curr Opin Cell Biol; 1998 Feb; 10(1):123-30. PubMed ID: 9484604
[TBL] [Abstract][Full Text] [Related]
18. From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics.
Mahaddalkar T; Lopus M
Curr Top Med Chem; 2017; 17(22):2559-2568. PubMed ID: 28056739
[TBL] [Abstract][Full Text] [Related]
19. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
Field JJ; Kanakkanthara A; Miller JH
Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
[TBL] [Abstract][Full Text] [Related]
20. Mitosis is not a key target of microtubule agents in patient tumors.
Komlodi-Pasztor E; Sackett D; Wilkerson J; Fojo T
Nat Rev Clin Oncol; 2011 Feb; 8(4):244-50. PubMed ID: 21283127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
